Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

Boston Scientific CorporationTrade
VanEck Rare Earth/Strategic MetalsTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs VanEck Rare Earth/Strategic Metals — how do they compare? Boston Scientific Corporation trades at $51.04 (market cap $74.19B), while VanEck Rare Earth/Strategic Metals trades at $77.3. The key difference: VanEck Rare Earth/Strategic Metals is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.

BSXREMX
Market Cap
$74.19B
Sector
HealthSector/Thematic
52-Week High
$108.14$109.53
52-Week Low
$42.63$56.60
Enterprise Value
$86.27B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.

Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.

VanEck Rare Earth/Strategic Metals

REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $77.52, down 1.19% today. The technical outlook is bullish based on moving averages, with a neutral oscillator reading. Recent news highlights U.S. efforts to build rare earth supply chain independence, with construction starting on Energy Fuels' Utah plant expansion (Forbes, 2026-08-04). The ETF provides exposure to 38 global rare earth companies but exhibits high volatility (~50% annualized) and turnover.

The long-term outlook for REMX is supported by geopolitical shifts and demand for critical minerals in technology and defense. However, risks include high volatility, China's dominance in the sector, and sensitivity to trade policies. Investors should weigh the growth potential against the ETF's speculative nature and lack of traditional fundamental metrics like P/E or P/S ratios.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About VanEck Rare Earth/Strategic Metals

REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.

Read more on REMX